Condition or Therapy:
Leukemia and lymphoma
Cancer and Blood Disorders
What is the goal of this study?
PLAT-03 is a phase 1 trial that will test the feasibility and safety of giving a series of 1 to 6 “booster” infusions called T cell antigen-presenting cells (T-APCs). These will be given to children and young adults after they receive their initial T-cell therapy on PLAT-02. The infusions of T-APCs are intended to make the patient’s reprogrammed cancer-fighting T cells last longer.
Who can join the study?
This study might be a good fit for children or young adults who:
- Are ages 1 to 26 years old
- Are enrolled in phase 2 of Seattle Children’s PLAT-02 trial
- Have been identified as being at risk for losing their reprogrammed T-cells shortly after T-cell therapy
- After receiving T cells through PLAT-02, have lost their reprogrammed T cells within 6 months
Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.
What happens in the study?
You can read more about the PLAT-03 study protocol at clinicaltrials.gov.
Who can I contact for information or to enroll?
Please email or call the research coordinator at 206-987-2106 to learn more about the study.
Seattle Children's Hospital main campus
Dr. Colleen Annesley